Dupilumab treatment led to significant SCORAD score reductions, with 37% achieving a 75% reduction and 72% reaching mild disease status by week 16. Improvements were observed as early as week 2, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback